Home › NDC Lookup › RxCUI directory › RxCUI 1442092

Allantoin 0.005 MG/MG Topical Gel [Mederma Advanced Scar] — RxCUI 1442092

RxNorm drug concept · Semantic branded drug
RxCUI 1442092 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1442092
Official nameAllantoin 0.005 MG/MG Topical Gel [Mederma Advanced Scar]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMederma Advanced Scar 0.5 % Topical Gel; Mederma Advanced Scar 0.005 MG/MG Topical Gel
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Allantoin 0.005 MG/MG Topical Gel [Mederma Advan... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Allantoin 0.005 MG/MG Topical Gel [Mederma Advanced Scar] RxCUI 1442092

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Allantoin 508
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mederma Advanced Scar 1442088
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Allantoin Topical Gel 1045329
    • Allantoin Topical Product 1154930
    • Allantoin Topical Gel [Mederma Advanced Scar] 1442090
    • Mederma Advanced Scar Topical Product 1442091
    • Topical Gel 346286
    • Topical Product 1151122
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Allantoin 0.005 MG/MG Topical Gel SCD · 1442087
  • Allantoin 0.005 MG/MG SCDC · 334318
  • Allantoin Topical Gel SCDF · 1045329
  • Allantoin Topical Product SCDG · 1154930

Brand-Name Concepts

  • Allantoin 0.005 MG/MG [Mederma Advanced Scar] SBDC · 1442089
  • Allantoin Topical Gel [Mederma Advanced Scar] SBDF · 1442090
  • Mederma Advanced Scar Topical Product SBDG · 1442091
  • Mederma Advanced Scar BN · 1442088

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1442092 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73302-0201-20 1 TUBE in 1 BOX (73302-201-20) / 20 g in 1 TUBE Mederma Advanced Scar HRA PHARMA AMERICA, INC. 2013-11-01
73302-0201-50 1 TUBE in 1 BOX (73302-201-50) / 50 g in 1 TUBE Mederma Advanced Scar HRA PHARMA AMERICA, INC. 2013-11-01
Observed labelers: HRA PHARMA AMERICA, INC. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.